Preclinical and post-treatment changes in the HCC-associated serum proteome

Ward, Douglas G.; Cheng, Ye; N’Kontchou, Gisèle; Thar, T T; Barget, Nathalie; Wei, Wenbin; Martin, Ashley; Beaugrand, Michel; Johnson, Philip J.

doi:10.1038/sj.bjc.6603429

Cited by 27 publications

(23 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Combined AFPand B2M estimation improved AUC for HCC diagnosis from 0.74 to 0.93.This goes with Ward et al (2006) where B2M was the most significantly HCC associated proteomic finding in their study. They mentioned that B2M might add power to a multi-marker HCC diagnostic panel and concluded that combined estimation of AFP and B2M might add a significant yield rather than B2M values alone for diagnosis of HCC.…”

Section: A Marker For Disease Progression In Egyptian Patients With Csupporting

confidence: 66%

Serum Beta-2 Microglobulin: a Possible Marker for Disease Progression in Egyptian Patients with Chronic HCV Related Liver Diseases

Ouda¹,

Khairy²,

Sorour³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Egypt has the highest prevalence of HCV infection in the world (~14.7%). Around 10-15% of HCV-infected persons will advance to cirrhosis within the first 20 years. The incidence of HCC is expected to grow in the next two decades, largely due to HCV related cirrhosis, and detection of HCC at an early stage is critical for a favorable clinical outcome. No simple reliable non-invasive marker has been available till now. B2M, a non-glycosylated polypeptide composed of 99 amino acids, is one of the components of HLA class I molecules on the surfaces of all nucleated cells. It has been reported that the level of serum B2M is elevated in patients with chronic hepatitis C and HCV-related HCC when compared to HCV-negative patients or healthy donors. Determining the clinical utility of serum Β2M as a marker for disease progression in Egyptian patients with HCV related chronic hepatitis, cirrhosis and hepatocellular carcinoma was the aim of the present study. Materials and Methods: In this analytical cross sectional study 92 participants were included in 4 equal groups: Group (1) non cirrhotic chronic HCV; Group (2) HCV related liver cirrhosis; Group (3) HCC on top of HCV,; and Group (4) healthy controls. History taking, clinical examination, routine labs and abdominal ultrasound were conducted for all patients, PCR and Metavir scores for group (1) patients, and triphasic CT abdomen and AFP for Group (3) patients. Β2M levels were measured in serum with a fully-automated IMX system. Results: The mean serum B2M level of Group (1) was 4.25±1.48 µg/ml., Group (2) was 7.48±3.04, Group (3) was 6.62±2.49 and Group (4) was 1.62±0.63. Serum B2M levels were significantly higher in diseased than control group (p<0.01) being significantly higher in cirrhosis (7.48±3.04) and HCC groups (6.62±2.49) than the HCV group (4.25±1.48) (p<0.01). There was a significant correlation between B2M Level and ALK, total and direct bilirubin and INR (p<0.05), and a significant inverse correlation between B2M level and albumin, total proteins, HB andWBCS values (p<0.05). There was no significant correlation between B2M level and viral load or Metavir score, largest tumour size or AFP (p>0.05). The best B2M cut-off for HCV diagnosis was 2.6 with a sensitivity of 100%, a specificity of 92%, a positive predictive value (PPV) of 97% and a negative predictive value (NPV) of 100%. The best B2M cut-off for HCC diagnosis was 4.55 which yielded sensitivity, specificity, positive predictive value, negative predictive values of 74%, 62%, 39.5, 87.8% respectively (p-value <0.01) while best cut-off for cirrhosis was 4.9, with sensitivity 74 % and specificity 74%.The sensitivity for HCC diagnosis increased upon B2M and AFP combined estimation to 91%, specificity to 79%, NPV to 95% and accuracy to 83%. Conclusions: Serum B2M level is elevated in HCV related chronic liver diseases and may be used as a marker for HCV disease progression towards cirrhosis and carcinoma.

show abstract

Section: A Marker For Disease Progression In Egyptian Patients With Csupporting

confidence: 66%

Serum Beta-2 Microglobulin: a Possible Marker for Disease Progression in Egyptian Patients with Chronic HCV Related Liver Diseases

Ouda¹,

Khairy²,

Sorour³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…However, their study included patients with a wide range of cancer diagnoses and radiation treatment plans and volumes [34]. Proteome changes in response to RT have been described for a number of malignancies including rectum [35], brain [31], head and neck [30,[36][37][38], prostate [39], skin [40], liver [41,42], and lung [43][44][45].…”

Section: Protein Biomarkers and Prostate Radiotherapy Response-singlementioning

confidence: 99%

Practical approaches to proteomic biomarkers within prostate cancer radiotherapy trials

Christensen

Evans²,

Ménard

et al. 2008

Cancer Metastasis Rev

View full text Add to dashboard Cite

show abstract

“…In a series of serum samples from 37 hepatitis C viral carrier patients before developing HCC, with HCC and following radiofrequency ablation of the tumor, 13 SELDI peaks changed significantly during HCC development [12]. β 2 -Microglobulin, a protein previously reported to be markedly elevated in patients with virus-related HCC, was also the most significant HCC-associated proteomic feature in this study.…”

Section: Serum Biomarkers For Hccmentioning

confidence: 79%

Biomarker Studies on Radiotherapy to Hepatocellular Carcinoma

et al. 2013

View full text Add to dashboard Cite

Radiotherapy (RT) has been gradually integrated into the multimodality treatment for hepatocellular carcinoma (HCC). The various patterns of failure in HCC patients undergoing RT drive the need of effective biomarkers to guide treatment decisions. Limited numbers of biomarkers have been investigated in HCC, with even fewer of them for patients treated by RT. Serum or plasma biomarkers measured by enzyme-linked immunosorbent assay were the most common practice. Of particular interest are those biomarkers that are detectable early in the course of radiotherapy which correlated with ultimate clinical outcome. Functional magnetic resonance imaging (MRI) is increasingly used to evaluate the imaging pattern indicative of disease control following RT. Positron emission tomography shows that pre-RT standard uptake values associate with various types of recurrence after treatment. Proximity ligation assay (PLA) is evolving with the unique features of dual-probe identification, ligation and amplification to allow the small volume of serum/plasma samples for evaluating multiple biomarkers. We demonstrate the screening work of biomarkers by PLA with pre- and post-RT serum samples from HCC patients undergoing RT. Efforts are being made to search for the potential biomarkers for HCC patients treated by RT.

show abstract

Preclinical and post-treatment changes in the HCC-associated serum proteome

Cited by 27 publications

References 31 publications

Serum Beta-2 Microglobulin: a Possible Marker for Disease Progression in Egyptian Patients with Chronic HCV Related Liver Diseases

Serum Beta-2 Microglobulin: a Possible Marker for Disease Progression in Egyptian Patients with Chronic HCV Related Liver Diseases

Practical approaches to proteomic biomarkers within prostate cancer radiotherapy trials

Biomarker Studies on Radiotherapy to Hepatocellular Carcinoma

Contact Info

Product

Resources

About